Dianthus Therapeutics, Inc.
DNTH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $726,245 | $53,596 | $23,682 | $243,423 |
| - Cash | $22,792 | $132,325 | $15,365 | $131,650 |
| + Debt | $1,491 | $585 | $788 | $0 |
| Enterprise Value | $704,944 | -$78,144 | $9,105 | $111,773 |
| Revenue | $6,235 | $2,826 | $6,417 | $1,476 |
| % Growth | 120.6% | -56% | 334.8% | – |
| Gross Profit | $6,235 | $2,826 | $6,417 | $1,476 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$101,452 | -$47,819 | -$29,558 | -$13,086 |
| % Margin | -1,627.1% | -1,692.1% | -460.6% | -886.6% |
| Net Income | -$84,969 | -$43,555 | -$28,476 | -$13,109 |
| % Margin | -1,362.8% | -1,541.2% | -443.8% | -888.1% |
| EPS Diluted | -2.55 | -8.45 | -7.6 | -3.82 |
| % Growth | 69.8% | -11.2% | -99% | – |
| Operating Cash Flow | -$78,180 | -$36,861 | -$29,070 | -$59,531 |
| Capital Expenditures | -$105 | -$110 | -$139 | -$1,264 |
| Free Cash Flow | -$78,285 | -$36,971 | -$29,209 | -$60,795 |